Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice

CompletedOBSERVATIONAL
Enrollment

8,662

Participants

Timeline

Start Date

June 1, 2013

Primary Completion Date

May 30, 2015

Study Completion Date

July 22, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

Donepezil Hydrochloride

Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.

Trial Locations (1)

Unknown

Multiple Locations

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02162264 - Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice | Biotech Hunter | Biotech Hunter